Our team will begin the evaluation of a novel drug that is administered intrathecally. It is a phase I trial with an oligonucleotide, administered intrathecally, which aims to reduce the formation of alfasinuclein, by inhibiting the LRKK2 gene.
An intranasal levodopa has been authorized in the US to treat off blockages, called Inbrija….
Levodopa infusion pump We evaluate an ultraconcentrated levodopa administered subcutaneously in patients with motor fluctuations….
Our Unit has achieved to be activated in this outstanding project and so serious pathology….
We appreciate the great effort made by our patients to contribute to the development of…
We have been activated in this trial that evaluates the safety of an innovative compound…